Current concepts on the pathogenesis of systemic amyloidosis

Nephrology Dialysis Transplantation

Volumn 11, Issue SUPPL. 9, 1996, Pages 53-62

  Bellotti, Vittorio ^a   Merlini, Giampaolo ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Amyloid protein; Immunoglobulin light chains; Pathogenesis; Protein folding unfolding; 2 microglobulin

Indexed keywords

AMYLOID; AMYLOID P COMPONENT; APOLIPOPROTEIN E; BETA 2 MICROGLOBULIN; PROTEOGLYCAN;

AMYLOIDOSIS; CONFERENCE PAPER; FIBER; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN FOLDING; PROTEIN STABILITY;

EID: 0030512066     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/11.supp9.53     Document Type: Conference Paper

References (117)

1. Glenner GG, Eanes ED, Bladen HA, Linke RP, Termine JD. β-Pleated sheet fibrils. A comparison of native amyloid with synthetic protein fibrils J Histochem Cytochem 1974; 22: 1141-1158
2. Glenner GG, Eanes ED, Page DL. The relation of the properties of Congo red-stained amyloid fibrils to the β-conformation. J Histochem Cytochem 1972; 20: 821-826
3. Bennhold H. Eine spezifische Amyloidfärbung mit Kongorot. München Med Wochenschr 1922; 69: 1537-1538
4. Divry P, Florkin M. Sur les propriétés optiques de l'amyloïde. C R Soc Biol 1927; 97: 1808-1810
5. Cohen AS, Calkins E. Electron microscopic observations on a fibrous component in amyloid of diverse origins. Nature 1959; 183: 1202-1203
6. Eanes ED, Glenner GG. X-ray diffraction studies on amyloid filaments. J Histochem Cytochem 1968; 16: 673-677
7. Lansbury PT. In pursuit of the molecular structure of amyloid plaque: new technology provides unexpected and critical information. Biochemistry 1992; 31: 6865-6870
8. Husby G, Araki S, Benditt EP et al. The 1990 guidelines for nomenclature and classification of amyloid and amyloidosis. In: Natvig JB, Førre Ø, Husby G, Husebekk A, Skogen B, Sletten K, Westermark P eds. Amyloid and Amyloidosis 1990. Dordrecht: Kluwer, 1991: 7-11
9. Kisilevsky R, Lyon AW, Young ID. A critical analysis of postulated pathogenetic mechanisms in amyloidogenesis. Crit Rev Clin Lab Sci 1992; 29: 59-82
10. Blake CC, Geisow M, Oatley S, Rerat B, Rerat C. Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 Å. J Mol Biol 1978; 121: 339-356
11. Hamilton JA, Steinrauf LK, Braden BC et al. The X-ray crystal structure refinements of normal human transthyretin and the amyloidogenic Val-30→Met variant to 1.7-Å resolution. J Biol Chem 1993; 268: 2416-2424
12. Sousa A, Andersson R, Drugge U, Holmgren G, Sandgren O. Familial amyloidotic polyneuropathy in Sweden: geographical distribution, age of onset, and prevalence. Hum Hered 1993; 43: 288-294
13. Thylén C, Wahlqvist J, Haettner E, Sandgren O, Holmgren G, Lundgren E. Modifications of transthyretin in amyloid fibrils: analysis of amyloid from homozygous and heterozygous individuals with the Met30 mutation. EMBO J 1993; 12: 743-748
14. Saraiva MJM, Birken S, Costa PP, Goodman DS. Amyloid fibril protein in familial amyloidotic polyneuropathy, Portuguese type. Definition of molecular abnormality in transthyretin (prealbumin). J Clin Invest 1974; 74: 104-109
15. Tawara S, Nakazato M, Kangawa K, Matsuo H, Araki S. Identification of amyloid prealbumin variant in familial amyloidotic polyneuropathy (Japanese type). Biochem Biophys Res Commun 1983; 116: 880-883
16. Jones LA, Harding JA, Cohen AS, Skinner M. New USA family has apolipoprotein AI (Arg26) variant. In: Natvig JB, Førre Ø, Husby G, Husebekk A, Skogen B, Sletten K, Westermark P eds. Amyloid and Amyloidosis 1990. Dordrecht: Kluwer, 1991: 385-388
17. Nichols WC, Dwulet FE, Liepnieks J, Benson MD. Variant apolipoprotein A-I as a major constituent of a human hereditary amyloid. Biochem Biophys Res Commun 1988; 156: 762-768
18. Vigushin DM, Gough J, Allan D el al. Familial nephropathic systemic amyloidosis caused by apolipoprotein AI variant Arg26. Q J Med 1994; 87: 149-154
19. Soutar AK, Hawkins PN, Vigushin DM et al. Apolipoprotein AI mutation Arg-60 causes autosomal dominant amyloidosis. Proc Natl Acad Sci USA 1992; 89: 7389-7393
20. Pepys MB, Baltz ML. Acute phase proteins with special reference to C-reactive protein and related proteins (pentraxins) and serum amyloid A protein. Adv Immunol 1983; 34: 141-212
21. Kisilevsky R. Heparan sulfate proteoglycans in amyloidogenesis: an epiphenomenon, a unique factor, or the tip of a more fundamental process? Lab Invest 1990; 63: 589-591
22. Snow AD, Kisilevsky R. Temporal relationship between glycosaminoglycan accumulation and amyloid deposition during experimental amyloidosis: a histochemical study. Lab Invest 1985; 53: 37-44
23. Paulsson M. Basement membrane proteins - structure, assembly, and cellular interaction. Crit Rev Biochem Mol Biol 1992; 27: 93-127
24. Lyon AW, Narindrasorasak S, Young ID et al. Co-deposition of basement membrane components during the induction of murine splenic AA amyloid. Lab Invest 1991; 64: 785-790
25. Pepys MB, Dash AC, Munn EA et al. Isolation of amyloid P-component (protein AP) from normal serum as a calcium-dependent binding protein. Lancet 1977; i: 1029-1031
26. Dyck RF, Lockwood CM, Kershaw M et al. Amyloid P-component is a constituent of normal human glomerular basement membrane. J Exp Med 1980; 152: 1162-1174
27. Breathnach SM, Melrose SM, Bhogal B et al. Amyloid P component is located on elastic fibre microfibrils in normal human tissue. Nature 1981; 293: 652-654
28. Emsley J, White HE, O'Hara BP et al. Structure of pentameric human serum amyloid P component. Nature 1994; 367: 338-345
29. Snow AD, Bramson R, Mar H, Wight TN, Kisilevsky R. A temporal and ultrastructural relationship between heparan sulfate proteoglycans and AA amyloid in experimental amyloidosis. J Histochem Cytochem 1991; 39: 1321-1330
30. Snow AD, Kisilevsky R. Temporal relationship between glycosaminoglycan accumulation and amyloid deposition during experimental amyloidosis: a histochemical study. Lab Invest 1985; 53: 37-44
31. Narindrasorasak S, Lowery D, Gonzalez-DeWhitt P, Poorman RA, Greenberg B, Kisilevsky R. High affinity interactions between the Alzheimer's β-amyloid precursor proteins and the basement membrane form of heparan sulfate proteoglycan. J Biol Chem 1991; 266: 12878-12883
32. Young ID, Willmer JP, Kisilevsky R. The ultrastructural localization of sulfated proteoglycans is identical in the amyloids of Alzheimer's disease and AA, AL, senile cardiac and medullary carcinoma-associated amyloidosis. Acta Neuropathol 1989; 78: 202-209
33. Magnus JH, Husby G, Kolset SO. Presence of glycosaminoglycans in purified AA type amyloid fibrils associated with juvenile rheumatoid arthritis. Ann Rheum Dis 1989; 48: 215-219
34. Magnus JH, Kolset SO, Husby G. High molecular weight glycosaminoglycans in AA type fibril extracts from human liver. Ann Rheum Dis 1991; 50: 562-566
35. Nelson SR, Lyon M, Gallagher JT, Johnson EA, Pepys MB. Isolation and characterization of the integral glycosaminoglycan constituents of human amyloid A and monoclonal light-chain amyloid fibrils. Biochem J 1991; 275: 67-73
36. Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K. Apolipoprotein E: immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res 1991; 541: 163-166
37. Strittmatter WJ, Saunders AM, Schmechel D et al. Apolipoprotein E: high affinity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer's disease. Proc Natl Acad Sci USA 1993; 90: 1977-1981
38. Wisniewski T, Frangione B. Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci Lett 1992; 135: 235-238
39. Buée L, Ding W, Anderson JP et al. Binding of heparan sulfate proteoglycan to Alzheimer's amyloid precursor protein is mediated in part by the N-terminal region of A4 peptide. Brain Res 1993; 627: 199-204
40. Fraser PE, Nguyen JT, Chin DT, Kirschner DA. Effects of sulfate ions on Alzheimer β/A4 peptide assemblies: implications for amyloid fibril-proteoglycan interactions. J Neurochem 1992; 59: 1531-1540
41. Snow AD, Mar H, Nochlin D, Kresse H, Wight TN. Peripheral distribution of dermatan sulfate proteoglycans (decorin) in amyloid-containing plaques and their presence in neurofibrillary tangles of Alzheimer's disease. J Histochem Cytochem 1992; 40: 105-113
42. De Beer MC, de Beer FC, McCubbin WD, Kay CM, Kindy MS. Structural prerequisites for serum amyloid A fibril formation. J Biol Chem 1993; 268: 20606-20612
43. McCubbin WD, Kay CM, Narindrasorasak S, Kisilevsky R. Circular-dichroism studies on two murine serum amyloid A proteins. Biochem J 1988; 256: 775-783
44. Aruga E, Ozasa H, Teraoka S, Ota K. Macromolecules that are colocalized with deposits of β2-microglobulin in hemodialysis-associated amyloidosis. Lab invest 1993; 69: 223-230
45. Stenstad T, Magnus JH, Kolset SO, Husby G. Sulfated polysaccharides in tissue and fibril extracts derived from various amyloids. In: Kisilevsky R, Benson MD, Frangione B, Gauldie J, Muckle TJ, Young ID eds. Amyloid and Amyloidosis 1993. Park Ridge, NJ: Parthenon, 1994: 192-194
46. Kisilevsky R. Amyloidogenesis - a critical review. In: Kisilevsky R, Benson MD, Frangione B, Gauldie J, Muckle TJ, Young ID eds. Amyloid and Amyloidosis 1993. Parthenon, Park Ridge, New Jersey: 1994: 9-12
47. Vandenabeele P, Fiers W. Is amyloidogenesis during Alzheimer's disease due to an lL-1/IL-6-mediated 'acute phase response' in the brain? Immunol Today 1991; 12: 217-219
48. Werdelin O, Ranlov P. Amyloidosis in mice produced by transplantation of spleen cells from casein-treated mice. Acta Pathol Microbiol Scand 1966; 68: 1-18
49. Hardt F, Ranlov P. Transfer amyloidosis. Int Rev Exp Pathol 1976; 16: 273-334
50. Sipe JD: Amyloidosis. Annu Rev Biochem 1992; 61: 947-975
51. Axelrad MA, Kisilevsky R, Willmer J, Chen SJ, Skinner M. Further characterization of amyloid-enhancing factor. Lab Invest 1982; 47: 139-146
52. Yokota T, Takahashi M, Ishihara T et al. Amyloid enhancing factor (AEF). Isolation and biochemical and pathological characteristics. Acta Pathol Jpn 1991; 41: 798-805
53. Kisilevsky R, Gruys E, Shirahama T. Does amyloid enhancing factor (AEF) exists? Is AEF a single biological entity? Amyloid Int J Exp Clin Invest 1995; 2: 128-133
54. Niewold ThA, Gruys E, Kisilevsky R, Shirahama TS. Fibril amyloid enhancing factor (FAEF)-accelerated amyloidosis in the hamster is not dependent on serine esterase activity and mononuclear phagocytosis. Scand J Immunol 1991; 34: 101-107
55. Alizadeh-Khiavi K, Normand J, Chronopoulos S et al.. Alzheimer's disease brain-derived ubiquitin has amyloidenhancing factor activity - behavior of ubiquitin during accelerated amyloidogenesis. Acta Neuropathol 1991; 81: 280-286
56. Varga J, Flinn MSM, Shirahama T, Rodgers OG, Cohen AS. The induction of accelerated murine amyloid with human splenic extract. Probable role of amyloid enhancing factor. Virchow's Arch Cell Pathol 1986; 51: 177-185
57. Ali-Khan Z, Quirion R, Robitaille Y, Alizadeh-Khiavi K, Du T. Evidence for increased amyloid enhancing factor activity in Alzheimer brain extract. Acta Neuropathol 1988; 77: 82-90
58. Niewold ThA, Hol PR, van Andel ACJ, Lutz ETG, Gruys E. Enhancement of amyloid induction by amyloid fibril fragments in hamster. Lab Invest 1987; 56: 544-549
59. Gajdusek DC. The transmissible amyloidoses: genetic control of spontaneous generation of infectious amyloid proteins by nucleation of configurational change in host precursors: Kuru-CJD-GSS-Scrapie-BSE. Eur J Epidemiol 1991; 7: 567-577
60. Prusiner SB. Genetic and infectious prior diseases. Arch Neurol 1993; 50: 1129-1153
61. Solomon A, Weiss DT: AL amyloidosis. In: Kisilevsky R, Benson MD, Frangione B, Gauldie J, Muckle TJ, Young ID eds. Amyloid and Amyloidosis 1993. Park Ridge, NJ: Parthenon, 1994: 200-205
62. Benson MD. Pathofibrillogenesis and amyloid proteins. In: Natvig JB, Førre Ø, Husby G, Husebekk A, Skogen B, Sletten K, Westermark P eds. Amyloid and Amyloidosis 1990. Dordrecht: Kluwer, 1991: 481-486
63. Wilkins Stevens P, Raffen R, Hanson DK et al. Recombinant immunoglobulin variable domains generated from synthetic genes provide a system for in vitro characterization of light-chain amyloid proteins. Protein Sci 1995; 4:421-432
64. Stevens FJ, Myatt EA, Chang C-H et al. A molecular model for self-assembly of amyloid fibrils: immunoglobulin light chains. Biochemistry 1995; 34: 10697-10702
65. Isobe T, Osserman EF Patterns of amyloidosis and their association with plasma-cell dyscrasias, monoclonal immunoglobulins and Bence Jones proteins. N Engl J Med 1974; 290: 473-477
66. Marinone G, Quaglini S, Bellotti V et al. AL amyloidosis: clinical and therapeutic aspects of an Italian study protocol. In: Kisilevsky R, Benson MD, Frangione B, Gauldie J, Muckle TJ, Young ID eds. Amyloid and Amyloidosis 1993. Park Ridge, NJ: Parthenon, 1994: 206-208
67. Solomon A, Frangione B, Franklin EC. Bence Jones proteins and light chain of immunoglobulins. Preferential association of the λVI subgroup of human light chains with amyloidosis AL. J Clin Invest 1982; 70: 453-460
68. Dwulet FE, Strako K, Benson MD. Amino acid sequence of a λ VI primary (AL) amyloid protein (WLT). Scand J Immunol 1985; 22: 653-660
69. Dwulet FE, O' Connors TP, Benson M. Polymorphism in a kappa I primary (AL) amyloid protein (BAN). Mol Immunol 1986; 23: 73-78
70. Ferri G, Stoppini M, Iadarola P, Bellotti V, Merlini G. Structural characterization of k II Inc, a new amyloid immunoglobulin. Biochim Biophys Acta 1989; 995: 103-108
71. Liepnieks JJ, Benson MD, Dwulet FE: Comparison of the amino acid sequences of ten kappa I amyloid proteins for amyloidogenic sequences. In: Natvig JB, Førre Ø, Husby G, Husebekk A, Skogen B, Sletten K, Westermark P eds. Amyloid and Amyloidosis 1990. Dordrecht: Kluwer, 1991: 153-156
72. Hurle MR, Helms LR, Li L, Chan W, Wetzel R. A role for destabilizing amino acid replacements in light-chain amyloidosis. Proc Natl Acad Sci USA 1994; 91: 5446-5450
73. Bellotti V, Merlini G, Bucciarelli E, Perfetti V, Quaglini S, Ascari E. Relevance of class, molecular weight and isoelectric point in predicting human light chain amyloidogenicity. Br J Haematol 1990; 74: 65-69.
74. Sletten K, Natvig JB, Husby G, Juul J. The complete amino acid sequence of a prototype immunoglobulin-λ light chain type amyloid-fibril protein AR. Biochem J 1981; 195: 561-572
75. Aucouturier P, Khamlichi AA, Preud'homme JL, Bauwens M, Touchard G, Cogné M. Complementary DNA sequence of human amyloidogenic immunoglobulin light chain precursors. Biochem J 1992; 285: 149-152
76. Wetzel R, Chan W, Lee G, Helms L, Hensley P. Fibril formation in vitro in mutants of REI, an immunoglobulin VL (Bence Jones) domain expressed in Escherichia coll.. In: Kisilevsky R, Benson MD, Frangione B, Gauldie J, Muckle TJ, Young ID eds. Amyloid and Amytoidosis 1993. Park Ridge, NJ: Parthenon, 1994: 513-516
77. Benson MD, Hamilton J, Braden B, Liepnieks J, Murrell J. X-ray crystallographic analysis of an AL kappa light chain to a 2Å resolution. In: Kisilevsky R, Benson MD, Frangione B, Gauldie J, Muckle TJ, Young ID eds. Amyloid and Amyloidosis 1993. Park Ridge, NJ: Parthenon, 1994: 218-220
78. Pras M, Schubert M, Zucker-Franklin D, Rimon A, Franklin EC. The characterization of soluble amyloid prepared in water. J Clin Invest 1968; 47: 924-933
79. Eulitz M. Amyloid formation from immunoglobulin chains. Biol Chem Hoppe-Seyler 1992; 373: 629-633
80. Eulitz M, Breuer M, Eblen A, Weiss DT, Solomon A. Production of amyloidogenic peptides from human immunoglobulin light (L)-chains. In: Natvig JB, Førre Ø, Husby G, Husebekk A, Skogen B, Sletten K, Westermark P eds. Amyloid and Amyloidosis 1990. Dordrecht: Kluwer, 1991: 505-510
81. Merlini GP, Mastanduno M, Moy PW, Osserman EF. Immunoglobulin light chain fragments in the serum and urine of patients with AL amyloidosis (abstract). Clin Research 1985; 33: 559A
82. Buxbaum J. Aberrant immunoglobulin synthesis in light chain amyloidosis. J Clin Invest 1986; 78: 798-806
83. Preud'homme JL, Ganeval D, Grünfeld JP, Striker L, Brouet JC. Immunoglobulin synthesis in primary and myeloma amyloidosis. Clin Exp Immunol 1988; 73: 389-394
84. Durie BG, Persky B, Soehnlen BJ, Grogan TM, Salmon SE. Amyloid production in human myeloma stem-cell culture, with morphologic evidence of amyloid secretion by associated macrophages. N Engl J Med 1982; 307: 1689-1692
85. Kisilevsky R, Narindrasorasak S, Tape C, Tan R, Boudreau L. During AA amyloidogenesis is proteolytic attack on serum amyloid A a pre- or post- fibrillogenic event? Amyloid Int J Exp Clin Invest 1994; 1: 174-183
86. Klafki HW, Kratzin HD, Pick AI, Eckart K, Karas M, Hilschmann N. Complete amino acid sequence determinations demonstrate identity of the urinary Bence Jones protein (BJP-DIA) and the amyloid fibril protein (AL-DIA) in a case of AL amyloidosis. Biochemistry 1992; 31: 3265-3272
87. Klafki HW, Pick AI, Pardowitz I, et al. Reduction of disulfide bonds in an amyloidogenic Bence Jones protein leads to formation of amyloid like fibrils in vitro. Biol Chem Hoppe-Seyler 1993; 374: 1117-1122
88. Rodilla SE, Kratzin HD, Pick AI, Hilschmann N. Biclonality in amyloidosis patient MAL: one clone producing an amyloidogenic, the other a non amyloidogenic kappa light chain. In: Natvig JB, Førre Ø, Husby G, Husebekk A, Skogen B, Sletten K, Westermark P eds. Amyloid and Amyloidosis 1990. Dordrecht: Kluwer, 1991: 161-164
89. Bellotti V, Stoppini M, Perfetti V et al. Use of anti-idiotypic monoclonal antibody in studying amyloidogenic light chains in cells, urine and fibrils: pathophysiology and clinical implications. Scand J Immunol 1992; 36: 607-615
90. Linke RP. An antiserum against the λ Bence Jones protein ZIM having idiotypic and C-region specificity does not immunostain the Aλ (ZIM) amyloid fibrils in tissue sections. In: Kisilevsky R, Benson MD, Frangione B, Gauldie J, Muckle TJ, Young ID eds. Amyloid and Amyloidosis 1993. Park Ridge, NJ: Parthenon, 1994: 253-255
91. Abrahamson M, Grubb A. Increased body temperature accelerates aggregation of the Leu-68→Gln mutant cystatin-C, the amyloid-forming protein in hereditary cystatin C amyloid angiopathy. Proc Natl Acad Sci USA 1994; 91: 1416-1420
92. Osserman EF, Takatsuki K, Talal N. The pathogenesis of 'amyloidosis': studies on the role of abnormal gamma globulins and gamma globulin fragments of the Bence Jones (L-polypeptide) type in the pathogenesis of 'primary' and 'secondary amyloidosis' and the 'amyloidosis' associated with plasma cell myeloma. Semin Hematol 1964; 1: 3-85
93. Sletten K, Westermark P, Husby G. Structural studies of the variable region of immunoglobulin light-chain-type amyloid fibril proteins. In: Glenner GG, Osserman EF, Bendit EP, Calkins E, Cohen AS, Zucker-Franklin D eds. Amyloidosis. New York: Plenum, 1986: 463-475
94. Holm E, Sletten K, Husby G. Structural studies of a carbohydrate containing immunoglobulin-λ-light chain amyloid fibril protein (AL) of variable subgroup III. Biochem J 1986; 239: 545-551
95. Kratzin HD, Pick AI, Hilschmann N. Complete amino acid sequence of a kappa light chain fragment isolated from the urine of amyloidosis patient MAL. In: Natvig JB, Førre Ø, Husby G, Husebekk A, Skogen B, Sletten K, Westermark P eds. Amyloid and Amyloidosis 1990. Dordrecht: Kluwer, 1991: 165-168
96. Wallik SC, Kabat E, Morrison S. Glycosylation of a VH residue of a monoclonal antibody against α(1-6) dextran increases its affinity for antigen. J Exp Med 1988; 168: 1099-1109
97. Omtvedt LA, Haavik S, Cohen EH, Sletten K. Elucidation of the oligosaccharide structure linked to the AL chain EPS. In: Kisilevsky R, Benson MD, Frangione B, Gauldie J, Muckle TJ, Young ID eds. Amyloid and Amyloidosis 1993. Park Ridge, NJ: Parthenon, 1994: 241-243
98. Toft KG, Olstad OK, Sletten K, Westermark P. Comparative studies of two AL chains of kappa-III light chain origin with and without attached carbohydrate (AL So 124 and AL 700). In: Natvig JB, Førre Ø, Husby G, Husebekk A, Skogen B, Sletten K, Westermark P eds. Amyloid and Amyloidosis 1990. Dordrecht: Kluwer, 1991: 169-172
99. Saper MA, Bjorkman PJ, Wiley DC. Refined structure of the human histocompatibility antigen HLA at 2.6 Å resolution. J Mol Biol 1991; 219: 277-319.
100. Stein G, Sperschneider H, Funfstuck R, Ritz E. Haemodialysis associated β2M amyloidosis: current controversies Nephrol Dial Transplant Suppl, 1994; 3: 48-50
101. Sharon EA, Fenske NA, Glass LF, Brozena SJ, Szakacs JE. Atypical β2-microglobulin amyloidosis following short-term hemodialysis. Am J Dermopathol 1994; 116: 179-184
102. Connors LH, Shirahama T, Skinner M, Fenves A, Cohen AS. In vitro formation of amyloid fibrils from intact β2 microglobulin. Biochem Biophys Res Commun 1985; 131: 1063-1068
103. Campistol JM, Solé M, Bombi JA et al. In vitro spontaneous synthesis of β2 microglobulin amyloid fibrils in peripheral blood mononuclear cell culture. Am J Pathol 1992; 141: 241-247
104. Miyata T, Inagi R, Wada Y et al. Glycation of human β2-microglobulin in patients with hemodialysis associated amyloidosis: identification of the glycated sites. Biochemistry 1994; 33: 12215-12221
105. Linke RP, Hampl H, Lobeck H et al. Lysine-specific cleavage of β2-microglobulin in amyloid deposits associated with hemodialysis. Kidney Int 1989; 36: 675-681
106. Linke RP, Bommer J, Ritz E, Waldherr R, Eulitz M. Amyloid kidney stones of uremic patients consists of beta 2 microglobulin fragments. Biochem Biophys Res Commun 1986; 136: 665-671
107. Capeillere-Blandin C, Delaveau T, Descamps-Latscha B. Structural modifications of human β2-microglobulin treated with oxigen-derived radicals. Biochem J 1991; 277: 175-182
108. Miyata T, Inagi R, Iida Y et al. Involvement of β2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. J Clin Invest 1994; 93:521-528
109. 2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. J Clin Invest 1993; 92:1243-1252
110. Burke MJ, Rougvie MA. Cross-β protein structures. I. Insulin fibrils. Biochemistry 1972; 11: 2435-2439
111. Gustavsson Å, Engstrom U, Westermark P. Normal transthyretin and synthetic transthyretin fragments form amyloid-like fibrils in vitro. Biochem Biophys Res Commun 1991; 175: 1159-1164
112. Linke RP, Zucker-Franklin D, Franklin EC. Morphologic, chemical, and immunologic studies of amyloid like fibrils formed from Bence Jones proteins by proteolysis. J Immunol 1973; 111: 10-23
113. Terzi E, Holzemann G, Seelig J. Reversible random coil-β sheet transition of the Alzheimer β-amyloid fragment (25-35). Biochemistry 1994; 33: 1345-1350
114. Merlini G, Ascari E, Amboldi N, et al. Interaction of the anthracycline 4′-iodo-4′-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis. Proc Natl Acad Sci USA 1995; 92: 2959-2963
115. Gianni L, Bellotti V, Gianni AM, Merlini G. New drug therapy of amyloidoses: resorption of AL-type deposits with 4′-iodo-4′-deoxydoxorubicin. Blood 1995; 86: 855-861
116. Kisilevsky R, Lemieux LJ, Fraser PE, Kong X, Hultin PG, Szarek WA. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implication for Alzheimer's disease. Nature Med 1995; 1: 143-148
117. Glenys AT, Lovat LB, Pepys MB. Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc Natl Acad Sci USA 1995; 92: 4299-4303